Fig. 1

Mice deficient for M3R were not protected from clinical signs of arthritis. a Clinical arthritis score for WT and M3R^−/− mice with CAIA. Male (n = 6 for each genotype) and female (n = 4 for each genotype) mice of the respective CAIA group were taken for analysis. The cumulative arthritis score (CAS) on each day of experiment is represented as mean ± SEM. b Incidence of arthritis development in male (n = 6 for each genotype) and female (n = 4 for each genotype) WT and M3R^−/− mice with CAIA. Incidence is given as percentage of mice per group that reached a CAS ≥ 4 on the indicated day of experiment. c Total physical condition score of male LPS control (n = 5 for each genotype) and arthritic (CAS ≥ 4) WT (n = 4) and M3R-deficient (n = 5) mice. The total condition score for every day of experiment is given as mean ± SEM. Asterisks indicate statistical significance (*P < 0.05: CAIA vs. respective LPS control; ^# P < 0.01: M3R^−/−-CAIA vs. WT-CAIA). d Average body weight of male LPS control and arthritic M3R^−/− and WT mice. For each group the average percentage of body weight throughout the experiment compared to experimental day 0 is given as mean ± SEM. *P < 0.05: CAIA vs. respective LPS control; ^# P < 0.05: M3R^−/−-CAIA vs. WT-CAIA. CAIA collagen antibody-induced arthritis, LPS lipopolysaccharide, M3R M3 muscarinic acetylcholine receptor, WT wild-type